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IL-12p70–producing patient DC vaccine elicits
Tc1-polarized immunity
Beatriz M. Carreno,1 Michelle Becker-Hapak,1 Alexander Huang,1 Megan Chan,1 Amer Alyasiry,1
Wen-Rong Lie,2 Rebecca L. Aft,3 Lynn A. Cornelius,4 Kathryn M. Trinkaus,5 and Gerald P. Linette1
1Department

2EMD

of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Millipore, St. Charles, Missouri, USA. 3Department of Surgery, 4Department of Medicine, Division of Dermatology,
and 5Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.

Background. Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but doselimiting toxicities have hindered its incorporation in vaccine formulations. Here, we report on the immunological
and clinical outcomes upon vaccination with CD40L/IFN-γ–matured, IL-12p70–producing DCs.
Methods. 7 HLA-A*0201+ newly diagnosed stage IV melanoma patients were immunized against the gp100 melanoma antigen using autologous peptide-pulsed, CD40L/IFN-γ–matured DCs. PBMCs were taken weekly for immune
monitoring by tetramer analysis and functional assays. CT imaging was performed at baseline, week 9, and week 18
for clinical assessment using RECIST.
Results. 6 of 7 treated patients developed sustained T cell immunity to all 3 melanoma gp100 antigen–derived peptides. 3 of the 6 immunological responders developed confirmed clinical responses (1 complete remission >4 years,
2 partial response). Importantly, DC vaccine–derived IL-12p70 levels positively correlated with time to progression
(P = 0.019, log-rank), as did T-cytotoxic 1 (Tc1) immunity, as assessed by IFN-γ/IL-13 and IFN-γ/IL-5 ratios (P = 0.035
and P = 0.030, respectively, log-rank). In contrast, a pathway-specific defect in IL-12p35 transcription was identified
upon CD40L/IFN-γ activation in clinical nonresponder patient DCs, and gp100-specific T cells from these patients
displayed a Tc2 phenotype. Incorporation of TLR3 and TLR8 agonists into the CD40L/IFN-γ activation protocol
corrected the IL-12p70 production defect in DCs derived from clinical nonresponder patients.
Conclusion. These findings underscore the essential role of IL-12p70 in the development of therapeutic type 1 antigen–specific CD8+ T cell immunity in humans with cancer.
Trial registration. Clinicaltrials.gov NCT00683670.
Funding. Barnes-Jewish Hospital Foundation, Siteman Cancer Frontier Fund, Washington University/JNJ Translational Medicine Award, and NCI (P30 CA91842).
Introduction
DCs are widely regarded as the most potent antigen-presenting
cells to initiate T cell immunity. Although immature DCs (iDCs)
can process and present antigens, these cells fail to produce proinflammatory cytokines, and thus have been shown to be tolerogenic in steady state, or at best weakly immunogenic (1). Stimulation of iDCs with bacterial products, T cell–derived signals,
and/or inflammatory agonists triggers a differentiation process
(“maturation”), accompanied by the expression of costimulatory
molecules and cytokines, which shapes the nature and magnitude
of T cell–mediated immunity (2). Due to this critical role in the
innate-to-adaptive immune transition, vaccines using DCs have
been evaluated in the treatment of patients with metastatic melanoma; however, these clinical studies have been disappointing,
with objective response rates less than 10% (3). Multiple factors
contribute to the limited success of DC vaccination in melanoma,
including the tumor microenvironment, Treg-mediated suppression, immune senescence, as well as incomplete maturation of the
DCs used for immunization (4, 5). To date, the majority of DC
vaccine studies have used either iDCs (GM-CSF/IL-4) or partially
matured DCs (GM-CSF/IL-4 plus activation by IL-1β, IL-6, TNF-α,
Conflict of interest: Wen-Rong Lie is an employee at EMD Millipore.
Citation for this article: J Clin Invest. 2013;123(8):3383–3394. doi:10.1172/JCI68395.

and/or PGE-2), which express costimulatory molecules but fail to
produce IL-12p70 (6). Production of bioactive IL-12p70 requires
the coordinated transcriptional regulation of genes encoding the
IL-12p35 and IL-12p40 subunits (7). Transcriptional activation of
IL-12p70 is dependent on 2 signals: one initiated by CD40 or TLR
and the other initiated by IFN-γ (8–10). While both signals are necessary for IL-12p35 transcriptional activation, IL-12p40 activation
is less dependent on IFN-γ signals. Studies using artificial antigenpresenting cells provided the initial evidence for the critical role
of IL-12p70, in conjunction with antigen and B7 costimulation,
for naive CD8+ T cell expansion and acquisition of effector function (11). Subsequent work in preclinical models confirmed the
role of IL-12p70 as a third signal for T cell activation and later
demonstrated that either IL-12p70 or type I IFN was necessary
for the development of type 1 CD8+ T cells (12, 13). Among CD8+
T cells responding to antigen and costimulation, IL-12p70 signaling enforces a gene regulation program that promotes chromatin
remodeling and induction of transcription factors, such as T-bet
and Eomes, that are important in the differentiation program of
this polarized T cell population, defined as the T-cytotoxic 1 (Tc1)
phenotype (14). Systemic administration of IL-12p70 has been
demonstrated to have antitumor activity in various preclinical animal models as well as modest activity in cancer patients when given
alone or with cancer vaccines (15–17). However, dose-limiting
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Table 1
Patient characteristics and immunological and clinical outcomes
Patient Sex AgeA StageB

Site of metastasis

P1
P2
P3
P4
P5
P6
P7

Subcutaneous (multiple), lymph node
Lung (multiple)
Lymph node
Subcutaneous (solitary)
Lung (multiple)
Liver (multiple)
Lung (multiple), subcutaneous (multiple)

M
M
M
F
M
M
M

47
70
53
50
53
38
36

4 (M1a)
4 (M1b)
4 (M1a)
4 (M1a)
4 (M1b)
4 (M1c)
4 (M1b)

Clinical status
Complete remission
Progressive disease
Progressive disease
Progressive disease
Partial response
Partial response
Progressive disease

TTPC

Immune responeD IL-12p70E

9/23/08; >1,416 d
1/16/09; 131 d
5/29/09; 81 d
1/15/10; 74 d
4/9/10; 352 d
4/13/10; 444 d
3/15/11; 63 d

325
311
4.4
62
240
301
295

104,794
902
63
287
2,101
2,065
793

AAt initiation of treatment (yr). BAccording to The American Joint Committee on Cancer staging system (2009 ed.). CDate of analysis, 08/05/12. Dgp100-specific T cell frequencies for weeks 0–9 (sum); see Figure 2. EProduction levels for D1–D3 (sum; pg/106 DCs/24 h); see Figures 1 and 4.

toxicities associated with systemic IL-12p70 administration have
hindered a wider incorporation into investigational cancer vaccine
formulations (18, 19).
Despite experimental evidence supporting the use of IL-12p70
as a vaccine adjuvant, current human DC vaccine formulations
fail to incorporate coordinated CD40/TLR/IFNR signaling as
part of the maturation process; thus, it remains to be determined
whether vaccination with functionally mature, IL-12p70–producing DCs confers a benefit to humans with cancer. Our aim was to
test the hypothesis that immunization with functionally mature,
IL-12p70–producing DCs would correlate with antigen-specific
immunity and clinical outcomes in patients with metastatic
melanoma. In this proof-of-concept clinical trial, patients with
newly diagnosed metastatic melanoma were immunized against
3 HLA-A*0201–restricted gp100 melanoma antigen–derived peptides (G154, G209-2M, and G280-9V) (20, 21) using autologous
peptide-pulsed, CD40L/IFN-γ–activated mature DCs (mDCs). In
this report, we characterized the induction of T cell immunity by
weekly longitudinal monitoring using PBMCs and investigated
biomarkers associated with clinical outcome.
Results
Patient-derived mDCs display varied IL-12p70 production upon CD40L/
IFN-γ activation. To assess the immunological and clinical outcomes upon vaccination with CD40L/IFN-γ–activated, IL-12p70–
producing mDCs, 7 newly diagnosed treatment-naive stage IV
melanoma patients were enrolled and treated in a pilot phase I
clinical trial (Table 1 and Figure 1A). Patients were not prescreened
for IL-12p70 production prior to enrollment. The schedule of
cyclophosphamide treatment, DC vaccinations, and immunemonitoring timelines is depicted in Figure 1B. Cyclophosphamide
treatment with a single dose (300 mg/m2 i.v.) given 3 days prior
to DC vaccination dose 1 (D1) did not significantly reduce Treg
frequencies (Supplemental Figure 2; supplemental material available online with this article; doi:10.1172/JCI68395DS1) or absolute lymphocyte counts (data not shown) in any of the 7 patients
treated. For D1, fresh PBMCs were initiated into culture for DC
generation; the remaining PBMCs were cryopreserved and used
to generate subsequent DC vaccine doses. 24 hours after CD40L/
IFN-γ activation, each mDC preparation was assessed for expression of various costimulatory molecules (CD80, CD83, and CD86;
data not shown) and cytokine production. Consistent with a previous report (22), DCs derived from cryopreserved PBMCs showed
reduced IL-12p70 production (Figure 1C). However, DCs generated from both fresh and frozen PBMCs, as prepared in our trial,
3384

retained functional capacity, as shown by their equivalent in vitro
stimulatory capacities (data not shown). More importantly, the
initial D1 (fresh DCs/fresh PBMCs) and subsequent booster doses
(fresh DCs/frozen PBMCs) of DC vaccines resulted in increased
frequencies of gp100 peptide–specific CD8+ T cells (Figure 2),
demonstrating this scheme to represent a good logistic approach
to DC vaccine manufacturing.
Unexpectedly, concentrations of IL-12p70 produced by mDCs
varied dramatically among patients (Figure 1C). For example,
patient 1 (P1) DCs produced a median of 37,700 pg/106 cells/24 h,
whereas DCs of P3 produced approximately 370-fold less (<100 pg/
106 cells/24 h). Note that the levels shown in Figure 1C (representing D1–D3) were consistent in all vaccine preparations. Diminished IL-12p70 production (<1,000 pg/106 cells/24 h) by patient
DCs upon CD40L/IFN-γ activation was not due to the inability of
these cells to respond to stimuli, as significant induction of IL-6,
IL-8, and TNF-α production was observed among normal/high
(>1 ng/106 cells/24 h) and low (<1 ng/106 cells/24 h) IL-12p70
producers (Supplemental Figure 3, A and B). Moreover, among
a panel of 42 cytokines and chemokines analyzed, no deficiency
other than IL-12p70 was observed in the patients studied (data
not shown).
CD40L/IFN-γ–activated mDC vaccination elicits gp100-specific T cell
immunity. To examine the kinetics and magnitude of T cell immunity to the gp100-derived peptides G154, G209-2M, and G280-9V
upon mDC vaccination, peripheral blood was collected prior to
vaccination and weekly thereafter (Figure 1B). Isolated PBMCs
were used to establish individual cultures for each of G154, G2092M, and G280-9V. The CD8+ T cell response to each peptide
antigen was analyzed using peptide/HLA*A0201 tetramers after
a single round of in vitro stimulation for 12 days. This immune
monitoring strategy allows for the reliable detection of vaccineinduced T cell responses in patients, as vaccine-induced T cell
frequencies are often below the lower limit of detection using current ex vivo assays with fresh PBMCs (23). Furthermore, it allows
for assessment of the replicative potential of vaccine-induced
T cells based on the multiple cell divisions required for cell expansion in vitro and detection by tetramer assay. Immune monitoring
after D4 was not shown, since the peak of the CD8+ T cell response
occurred within the first 9 weeks for all patients (Supplemental
Figure 4A). P5 and P7 had detectable immunity to all 3 gp100
peptides prior to vaccination, and these responses increased significantly after immunization (Figure 2). Surprisingly, the peak
T cell response was detected after 1 or 2 mDC vaccine doses in
most patients (Supplemental Figure 4A). However, the 2 patients
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Figure 1
Clinical trial scheme and ex vivo IL12p70 production by CD40L/IFN-γ–
activated DCs (mDCs). (A) Consort
diagram. (B) Study timelines depicting
cyclophosphamide treatment (300 mg/
m2 i.v.), DC vaccinations (D1–D6), and
PBMC sampling for immune monitoring.
(C) Ex vivo IL-12p70 levels produced by
patient-derived mDCs used for manufacturing D1–D3 (each symbol represent a
vaccine dose). DC supernatants were
harvested 24 hours after activation, and
IL-12p70 concentrations were determined by ELISA. D1 was manufactured
using fresh PBMCs (which consistently
produced the highest concentration of
cytokine) as the source of monocytes,
and D2–D6 were prepared using cryopreserved PBMCs. Results represent
mean ± SEM.

with the lowest gp100-specific T cell responses and the lowest DC
IL-12p70 production levels (P3 and P4) had delayed kinetics, with
the peak response detected after 3 vaccine doses (Figure 1C, Figure
2, and Supplemental Figure 4A). Analysis of CD8+ T cell responses
to individual gp100-derived peptides indicated that all patients
developed immunity to the G209-2M peptide (4.6%–48% CD8+
T cells), while all patients but P3 developed immunity to the G154
(<10% CD8+ T cells) and G280-9V (11%–70% CD8+ T cells) peptides
(Figure 2). Interestingly, CD8+ T cell frequencies in response to the
high-affinity G154 peptide were consistently lower than to those
observed for the low-affinity G209-2M and G280-9V peptides
(Supplemental Figure 4B). Overall, mDC vaccination resulted in a
significant increase in the gp100-specific T cell frequencies for all

3 peptides (Supplemental Figure 4B). Importantly, immunization
with CD40L/IFN-γ–activated mDCs pulsed with G209-2M and
G280-9V elicited antigen-specific CD8+ T cells that recognized the
naturally processed gp100 antigen and exhibited antigen avidity
(i.e., effective concentration at 50% maximal lysis) ranging 0.1–1
nM, as determined in standard 4-hour 51Cr release assays (Figure
3, A and B). These results suggest that 2 mDC doses are sufficient
for the induction of high-avidity T cells to native gp100 protein in
most patients. In the 3 patients that exhibited a confirmed clinical response (P1, P5, and P6; Table 1 and Supplemental Figure
5), gp100-specific memory T cell responses were detected 6–12
months after the last vaccination (Supplemental Figure 6), despite
the fact that ipilimumab followed by temozolomide and steroids
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Figure 2
Vaccine-induced CD8+ T cell responses. PBMCs isolated before DC vaccination (pre-vacc) and at peak (post-vacc; see Supplemental Figure 4
for kinetics) were cultured in vitro in the presence of peptide (40 μg/ml) and IL-2 (50 U/ml) for 12 days. Cultures were stained by addition of corresponding PE-conjugated tetramers (gp100 peptide/HLA-A*0201) followed by a lineage-negative cocktail (FITC-conjugated anti-CD4, -CD14,
-CD19, and -CD56) and allophycocyanin-conjugated anti-CD8. Viability dye 7AAD was added to gate out dead cells. Numbers within dot plots
represent percent G154 (A), G209-2M (B), and G280-9V (C) tetramer-positive cells in lymph+/CD8+ gated cells.

(P6), ipilimumab (P5), or no additional treatment (P1) had been
administered (see trial summary in the supplemental material).
IL-12p70 production by patient mDCs correlates with clinical outcome.
Of the 7 patients treated in this pilot trial, 3 had an objective
clinical response (P1, P5, and P6; Table 1) as assessed by Response
Evaluation Criteria in Solid Tumors (RECIST) criteria (24), and
each responding patient had time to progression (TTP) of >11.5
months. Cox regression analysis followed by likelihood-ratio test
revealed a positive correlation between ex vivo IL-12p70 production by CD40L/IFN-γ–activated mDCs and TTP (P = 0.0198; Figure
4). P1, the patient vaccinated with mDCs producing the highest
amounts of IL-12p70 (Table 1), remained in complete remission
>4 years after enrollment in the clinical trial (Supplemental Figure
5). In contrast, patients vaccinated with mDCs producing relatively
low amounts of IL-12p70 (<1 ng IL-12p70, sum D1–D3; Table 1)
had rapid disease progression, confirmed upon CT imaging per3386

formed after D3 or D6 (data not shown). Only those patients vaccinated with mDCs producing >1 ng IL-12p70 (Table 1) had clinical
benefit, as defined by increased TTP as well as tumor regression
(Supplemental Figure 5). In contrast, a similar analysis found
no significant correlation between IL-12p70 production and frequency of vaccine-induced T cell responses or between frequency of
vaccine-induced T cell responses and TTP in this study.
Vaccine-induced CD8+ T cell responses are qualitatively different between
clinical responders and nonresponders. Having determined that the magnitude of the vaccine-induced immune response did not correlate
with clinical benefit, next we examined whether immunization with
high/normal (>1 ng/106 cells/24 h) and low (<1 ng/106 cells/24 h)
IL-12p70–producing DCs influences the cytokine profiles of the
vaccine-induced T cells. G280-9V–specific CD8+ T cells were generated as previously described (25) and restimulated in an antigenspecific manner, and supernatants were collected at 20 hours and
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Figure 3
Vaccine-induced T cells recognize native gp100 and display high affinity for antigen. (A) PBMCs collected after D3 were cultured in the presence
of G209-2M (white bars and symbols) or G280-9V (black bars and symbols) peptide for 12 days as described in Figure 2 and tested in a standard
4-hour 51Cr release assay for their ability to recognize native gp100 antigen on human melanoma cells lines DM6 (HLA-A2 +gp100+) and A375
(HLA-A2+gp100–). Percent specific lysis at a 30:1 effector/target ratio is shown; spontaneous lysis was <10%. Results are representative of 2
experiments. (B) Avidity of G209-2M– and G280-9V–specific T cells was determined in a standard 4-hour 51Cr release assay using peptide titrations and T2 (HLA-A*0201+) cells as targets. Percent specific lysis is shown for each peptide concentration; spontaneous lysis was <5%. Results
are representative of 2 experiments.

tested by a multiplex (42-cytokine) bead assay. Examination of
IFN-γ, IL-5, and IL-13 production levels revealed 2 distinct cytokine
profiles among the 6 patients with immunological responses (P3
could not be evaluated because the frequency of gp100-specific
T cells was insufficient for analysis). In 1 group of patients (P1, P5,
and P6), IFN-γ production was dramatically higher than IL-5 and
IL-13, suggestive of a Tc1 bias immune response, while in another
group (P2, P4, and P7), higher IL-5 and IL-13 production amounts
with less IFN-γ was observed, consistent with a Tc2 bias (Figure 5,
A and B). When patients were grouped according to clinical benefit (clinical responder vs. nonresponder), significant differences
between these 2 groups were observed in IFN-γ/IL-13 and IFN-γ/
IL-5 ratios (P = 0.0356 and P = 0.0425, respectively; Figure 5C). The
high IFN-γ/IL-13 and IFN-γ/IL-5 ratios observed in the patients
immunized with high–IL-12p70–producing mDCs (P1, P5, and P6)
correlated with an objective clinical response (Table 1). Conversely,
vaccination with low–IL-12p70–producing mDCs resulted in a
Tc2-skewed response (low IFN-γ/IL-13 or IFN-γ/IL-5 ratio), which
may be ineffective at promoting tumor regression and correlated
with rapid disease progression. Importantly, Tc1 profiles positively
correlated with TTP (IFN-γ/IL-13, P = 0.035; IFN-γ/IL-5, P = 0.030;
Kaplan-Meier log-rank test), such that those patients with IFN-γ
in excess of IL-13 and IL-5 had the longest TTP. Other cytokines

associated with lineage commitment, such as IL-9, IL-10, and IL-17,
could not be detected in the supernatants of antigen-stimulated
gp100-specific CD8+ T cells from patients in this study (data not
shown). This observation provides evidence that vaccination with
IL-12p70–producing (>1 ng/106 cells/24 h) mDCs promotes type
1 immunity that can result in clinical benefit in newly diagnosed
patients, as defined by objective tumor regression and improved
progression-free survival.
Decreased IL-12p70 production results from impaired IL-12p35 gene
activation upon CD40L/IFN-γ stimulation. Having established a statistically significant correlation between IL-12p70 production
and clinical outcome (as measured by TTP; Figure 4), we formally
examined whether IL-12p70 production by DCs upon CD40L/
IFN-γ activation is defective among melanoma patients. iDCs
derived from 10 newly diagnosed treatment-naive stage IV melanoma patients and 10 age- and gender-matched healthy controls
were generated, then stimulated with CD40L/IFN-γ and supernatants collected 24 hours later. As shown in Figure 6A, and in
agreement with our previous results (26), mDCs from healthy
controls produced a median IL-12p70 concentration of 5.5 ng/106
cells/24 h; the highest IL-12p70 producer among healthy controls was 24 ng/106 cells/24 h. In contrast, mDCs derived from
melanoma patients produced a median IL-12p70 concentration
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Figure 4
IL-12p70 production and TTP. Cox regression analysis followed by likelihood-ratio test revealed a positive correlation between IL-12p70 production and TTP (P = 0.0198, log-rank). White symbols represent patients
with rapid disease progression. Black symbols represent patients with
confirmed clinical response (see Table 1). P1 showed complete remission as of 4 years after initiation of treatment (analysis performed on
08/05/12; asterisk); P5 and P6 showed a partial response, with disease
progression observed at or after 11.5 months of treatment initiation. No
correlation was observed between IL-12p70 production and immune
response or between immune response and clinical outcome.

of 0.65 ng/106 cells/24 h. This 8-fold decrease in median IL-12p70
production levels was statistically significant (P = 0.0420), despite
1 melanoma patient producing IL-12p70 levels of >30 ng/10 6
cells/24 h. Moreover, mDCs from 7 of the 10 melanoma patients
produced IL-12p70 levels of <1 ng, while all healthy controls produced >1 ng (Figure 6A).
To better understand the basis for impaired production of bioactive IL-12 (IL-12p70, IL-12p35, and IL-12p40), we examined
the synthesis of IL-12p40 and IL-12p35. As IL-12p35 is secreted
exclusively as a subunit of the IL-12p70 heterodimer (1:1 ratio
with IL-12p40), bioactive IL-12 production is generally accepted
to be an indicator of IL-12p35 production (27). As shown in Figure 6B, IL-12p40 production was markedly induced in mDCs in
all patients (10.1–177 ng/106 cells/24 h). A 2.5-fold difference
was observed between the 25th and 75th quartiles (20.5 and 52.7
ng/106 cells/24 h, respectively), suggesting similar induction of
IL-12p40 production among patients. In contrast, IL-12p70 production varied substantially (45 pg–33 ng/106 cells/24 h) among
patients, with an 18-fold difference between the 25th and 75th
quartiles (63 and 1,170 pg/106 cells/24 h, respectively). These data
suggested that defective IL-12p35 expression might account for
the decreased IL-12p70 production. We sought to further confirm
this finding using quantitative real-time RT-PCR (qRT-PCR) using
mDCs from the clinical trial participants (no cells were available
for P4). As shown in Figure 6C, the IL-12p35 transcript was marginally induced (<3-fold) in DCs from the low IL-12p70 producers
(P2, P3, and P7), whereas a >15-fold increase was observed in DCs
derived from the high/normal IL-12p70 producers (P1, P5, and
P6). Together, these findings suggest that defective IL-12p35 gene
transcription observed upon CD40L/IFN-γ activation accounts
for the impaired IL-12p70 production by melanoma patient DCs.
Impaired IL-12p70 production by patient mDCs can be rescued by a
unique combination of innate and adaptive activating signals. Prior studies in healthy individuals have demonstrated that TLR agonists can
synergize with CD40L and/or IFN-γ (28–30) to stimulate IL-12p70
production. In an effort to correct the IL-12p35 deficiency observed
upon CD40L/IFN-γ activation, DCs derived from clinical trial participants were activated with CD40L/IFN-γ in combination with
3388

various TLR agonists and IL-12p70 production levels examined. In
preliminary experiments using single TLR agonists, we determined
that the TLR3 agonist poly I:C and the TLR8 agonist R848 were
equipotent when added as single agonists to CD40L/IFN-γ (data
not shown). Moreover, as shown in Figure 7A, poly I:C, R848, and
CD40L/IFN-γ in combination enhanced patient DC IL-12p70 production 5- to 160-fold above that of CD40L/IFN-γ activation alone.
Importantly, upon combined CD40L/IFN-γ, poly I:C, and R848
activation, IL-12p70 production by mDCs from P2, P3, P4, and P7
reached levels similar to those observed in healthy individuals (Figure 6A and Figure 7A). Thus, the IL-12p70 deficiency observed in
patient mDCs upon CD40L/IFN-γ activation appears to be pathway dependent, not reflective of an overall dysfunction in IL-12p35
transcription. Finally, as an additional test of functional competence, mDCs activated with CD40L/IFN-γ, poly I:C, and R848 in
combination were evaluated for their capacity to promote the ex
vivo expansion of antigen-specific T cells from selected vaccinated
patients. As shown in Figure 7, B and C, mDCs activated with combined CD40L/IFN-γ, poly I:C, and R848 enhanced IL-12p70 production and showed an improved capacity compared with CD40L/
IFN-γ activation alone, stimulating growth of gp100-specific CD8+
T cells and increasing T cell frequencies 2- to 4-fold, as assessed by
gp100/HLA-A*0201 peptide tetramer assay. Together, these results
demonstrated that the incorporation of poly I:C and R848 into the
DC maturation protocol improved IL-12p70 production by melanoma patient–derived DCs and may promote enhanced antigenspecific CD8+ T cell responses.
Discussion
A novel clinical-grade CD40L reagent was developed to test the
hypothesis that immunization with functionally mature IL12p70–producing DCs elicits effective CD8+ T immunity in
patients with newly diagnosed advanced melanoma. Immunological responses to the gp100 antigen were observed in 6 of the
7 treated patients, while clinical response (as defined by RECIST
criteria) was observed in 3 of 7 patients. Importantly, IL-12p70
levels produced by patient-derived CD40L/IFN-γ–activated mDCs
as well as the development of antitumor Tc1 CD8+ T cell immunity correlated with TTP. Impairment in IL-12p70 production
by CD40L/IFN-γ activated mDCs was observed in the 4 clinical
nonresponder patients (all with Tc2-skewed immunity), and this
deficiency resulted from impaired IL-12p35 subunit transcription.
However, incorporating TLR3 and TLR8 signals with CD40L/
IFN-γ activation corrected the IL-12p70 production defect in clinical nonresponder patient DCs, suggesting new ways to improve
vaccine efficacy in patients with cancer.
Progress in cancer immunotherapy has been hampered by the
lack of clinical-grade reagents available to investigators (31); thus,
to the best of our knowledge, this study represents the first DC vaccine trial to use the combination of trimeric (cell-bound) CD40L
with IFN-γ for ex vivo DC maturation prior to administration.
Previous human studies have used clinical-grade soluble trimeric
CD40L as a single agent applied to mDCs ex vivo (32, 33), but
neither reported or attempted to correlate IL-12p70 production
with immunological responses and/or clinical outcomes. More
recently, Okada et al. (34) demonstrated, in malignant glioma,
the immunogenicity and clinical activity of a poly-ICLC–boosted
α–type 1 polarized DC vaccine and correlated clinical benefit (as
determined by TTP) with the ability of these type 1 polarized DCs
to in vitro produce IL-12p70 upon CD40L activation. Our results
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Figure 5
gp100 antigen–specific T cells from clinical responders display a Tc1 phenotype. Purified CD8+ T cells were stimulated twice in vitro, and antigenspecific frequencies were determined by peptide/HLA-A*0201 tetramers. T cells were adjusted to 106 cell/ml and stimulated with antigen, and
supernatants were harvested at 20 hours. Cytokine production was determined as described in Methods. (A and B) Patients were grouped as
clinical responders (A) and nonresponders (B). To compare production of Tc1 (IFN-γ) and Tc2 (IL-5, IL-13) cytokines among patients, a cytokine
index was derived by dividing pg/ml IFN-γ by pg/ml IL-13 or IL-5. (C) Cytokine ratios differed among clinical responder and nonresponder patients.
P values (unpaired 2-tailed t test) are indicated. Results are representative of 2 experiments.

confirmed and extended these findings by providing additional
evidence in melanoma that immunization with antigen-loaded,
IL-12p70–producing DC vaccine resulted in the development of
Tc1 antigen-specific CD8+ T cell immunity that correlated with
clinical benefit, as defined by radiographic response (RECIST) and
improved TTP. Importantly, the 3 highest IL-12p70 producers (P1,
P5, and P6) in our trial were the only patients that had a radiographic response (1 complete remission, 2 partial response), and
each was associated with TTP of >11.5 months. In contrast, the
remaining 4 patients (P2, P3, P4, and P7) all had IL-12p70 production of <1 ng/106 cells/24 h and exhibited disease progression with
no evidence of tumor regression at any site. Thus, IL-12p70 production levels appear to be a biomarker of clinical benefit (Figure
4), which suggests that optimization of DC vaccine formulations
should consider incorporating measurement of IL-12p70 production as a surrogate of vaccine potency and efficacy (34, 35).
Despite several comparative studies in humans (3, 36), the optimal route of DC administration remains to be defined. Based on

immunological and clinical outcomes reported by Timmerman
et al. (37) using i.v. infused DCs in non-Hodgkin’s lymphoma, we
chose to administer CD40L/IFN-γ–activated mDCs by i.v. infusion.
Labeling studies in patients have shown that i.v. injected DCs traffic to the lung and subsequently redistribute to liver, spleen, and
bone marrow (38, 39). Interestingly, P6 presented multiple liver
metastases and achieved partial clinical response after vaccination, suggesting an effect of IL-12p70–producing DCs at or near
the hepatic lesions. Additionally, our results demonstrated that i.v.
administration of DCs induced T cell immunity, which suggests
that the quality of immune response maybe more dependent on
the maturation status of DCs than on the route of administration.
However, recent studies have suggested that other routes of vaccine
administration might be superior (40, 41); additional investigation
is warranted in this area to further optimize vaccine efficacy.
DC dysfunctions in cancer patients have been previously
described; most are predicated on tumor-derived factors that
suppress DC differentiation, maturation, or function within the
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Figure 6
IL-12p70 production and IL-12p35 transcription by mDCs derived from patients with melanoma. (A) DCs from age- and gender-matched healthy
donors (H) and melanoma patients (M) were activated with CD40L/IFN-γ for 24 hours, and supernatants were harvested and assayed for IL12p70 production by ELISA. Horizontal lines and error bars denote median and interquartile range. P value (Wilcoxon matched-pairs test) is
indicated. (B) Patient DCs were activated with CD40L/IFN-γ for 24 hours, supernatants were collected, and IL-12p40 and IL-12p70 production
was measured by ELISA. Results are shown for 10 melanoma patients. Horizontal lines and error bars denote median and interquartile range. (C)
To examine IL-12p35 gene activation, DCs were activated with CD40L/IFN-γ for 6 hours, cells were harvested and washed, and total RNA was
prepared. Total RNA was also prepared from iDCs. Using primers specific for IL-12p35 and CD11c (DC lineage marker), qRT-PCR was performed
and analyzed using the relative standard method. Results were normalized to CD11c, and values are expressed as fold IL-12p35 induction in
mDCs relative to iDCs. Results are representative of 2 experiments.

context of the tumor microenvironment (4, 42). The list of tumorderived factors includes IL-10, VEGF, M-CSF, TSLP, and TGF-β1
as well as prostaglandins and gangliosides (5, 43). The observed
defect in IL-12p70 synthesis upon CD40L/IFN-γ activation in 7
of 10 patients was also suggestive of a DC dysfunction, albeit one
that is likely dependent on activation method (CD40L/IFN-γ) and
perhaps independent of tumor-derived factors. Our observation
that incorporation of innate signals (TLR3 and TLR8 agonists)
to the activation protocol restored the capacity of patient’s DCs
to produce IL-12p70 at levels similar to those observed in healthy
individuals suggests the IL-12p35 deficiency to be pathway specific. Interestingly, defective IL-12p70 production by neonate
DCs has been proposed to account for impaired Th1 responses in
human newborns (44). In neonate DCs, similar to our study using
adult monocyte-derived DCs, selective deficiency in IL-12p70 production resulted from impaired IL-12p35 transcription upon activation. Goldman and coworkers have identified defective nucleosome remodeling (at the SP-1 site) of the IL-12p35 promoter and
lack of IRF-3 phosphorylation as mechanisms that may account
for impaired IL-12p35 transcription in newborn-derived DCs
(45, 46). However, IFN-γ treatment of neonate DCs can restore
IL-12p35 transcription and IL-12p70 synthesis. In contrast, in
melanoma patient–derived DCs, impaired IL-12p35 transcription
was corrected by addition of TLR agonists, but not by increasing
concentrations of IFN-γ (data not shown), which suggests that a
distinct mechanism may account for the impairment. Indeed, preliminary studies examining STAT-1 phosphorylation and nuclear
translocation of IFN-responsive factors (IRF-1, IRF-8, and IRF3) showed no defect in the IFN signaling pathway among DCs
derived from the nonresponder patients (data not shown).
Substantial evidence supports the hypothesis that Th2/Tc2
immune polarization correlates with worse disease outcome in
patients with cancer (47). Previous work using melanoma antigen-specific T cells from patients confirms an immune bias with
deviation toward the Th2/Tc2 phenotype (48–50). Interestingly,
this type 2 immune bias could be partially corrected by antigen
stimulation in vitro using IL-12p70–producing mDCs (48). Our
present results revealed that low–IL-12p70–producing mDCs, like
3390

water-in-oil emulsions such as Montanide (51), effectively primed
an immune response to the gp100 antigen; however, the quality of
the ensuing T cell response is insufficient to elicit tumor regression. Moreover, the magnitude or duration of CD8+ T cell immunity after immunization was not markedly influenced by IL-12p70
concentration — although P3, the patient that produced no detectable IL-12p70, developed weak, transient T cell immunity against
only G209-2M, whereas the remaining 6 patients developed sustained immunity against all 3 gp100-derived peptides. Rather, the
striking bias toward type 1 immunity among the normal/high IL12p70 producers was consistent with past observations in murine
models that show the direct causal influence of IL-12p70 on Th1
lineage commitment (52, 53). The positive correlation observed
between cytokine ratios (IFN-γ/IL-13 and IFN-γ/IL-5) and TTP
was a finding of key importance, providing further support for
IL-12p70 as a critical signal in the induction of therapeutic type 1
antigen-specific CD8+ T cell immunity in patients. Our data may
also provide an explanation for the limited success of various adjuvants, as well as past DC vaccine trials in cancer, which have not
incorporated IL-12p70 (3, 54). Future studies using DC activation
protocols incorporating sequential activation signals, such as TLR3
and TLR8 agonists, with CD40L/IFN-γ should lead to enhanced
IL-12p70 production, which is predicted by various investigators to
elicit therapeutic antitumor type 1 immunity (2, 55–57).
Sample size estimates for investigator-initiated, first-in-human
clinical trials has become a topic of contention, driven principally
by the requirement for statistical power balanced by investigation of a biologic proof of principle (58). Implicit in the testing
of novel protein-, gene-, or cell-based therapies at single academic
medical centers is cost. The results of our study support a model
of adaptive clinical development that requires initial testing of
expensive therapeutics in a limited number of patients selected
on the basis of phenotype (disease) or genotype with a focus on
discovery, rather than a well-defined regulatory endpoint. Recent
examples that highlight a similar approach of evaluating novel cell
therapies in a limited number of patients include trials with chimeric antigen receptor T cell gene therapy for leukemia (59) and
α-galactosylceramide–loaded DC vaccination for myeloma (60).
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Figure 7
IL-12p70 production and ex vivo antigen-specific T cell responses stimulated by CD40L/IFN-γ + poly I:C + R848–activated DCs. (A) iDCs were
stimulated for 24 hours with CD40L/IFN-γ (mDCs), alone or in combination with poly I:C (5 μg/ml; TLR3 agonist) and R848 (5 μg/ml; TLR8 agonist), and supernatants were assayed for IL-12p70. Results are those obtained in 2 experiments. P values (paired 2-tailed t test) are indicated.
(B and C) DCs derived from P3 and P4 were activated for 24 hours with CD40L/IFN-γ, alone or in combination with poly I:C and R848, and
supernatants were analyzed for IL-12p70. Additionally, activated DCs were pulsed with G280-9V peptide (40 μg/ml) and used for stimulation of
purified CD8+ T cells (see Methods). G280-9V–specific T cell frequencies within the CD8+ T cell population was determined at day 12 using YLE/
HLA-A*0201 tetramers and anti-CD8 mAb. Results are representative of 3 experiments.

In summary, this proof-of-concept clinical study provided evidence
that IL-12p70 produced by antigen-loaded mDCs dictates T cell lineage commitment toward the Tc1 (versus Tc2) phenotype, which then
influences disease response (or progression) among patients with
minimal tumor burden. These results highlight the critical role of IL12p70 in developing CD8+ T cell immunity and the potential value of
this cytokine as a surrogate for vaccine efficacy and also suggest new
strategies to enhance T cell immunity in patients with cancer.

Methods
Human subjects. Eligible adult patients with newly diagnosed treatmentnaive (ECOG performance status 0) stage IV cutaneous melanoma were
enrolled in this clinical trial. All subjects were HLA-A*0201+, had gp100+
biopsy-proven (HMB45+, immunohistochemistry) melanoma metastases,
had no evidence of autoimmune disorder, and were negative for HIV, HBV,
and HCV. Leukapheresis was performed to obtain PBMCs from patients
and healthy donors through the Barnes Jewish Hospital blood bank. For
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trial patients, leukapheresis was performed prior to treatment and after D3
and D6. Patients were not prescreened for IL-12p70 DC production prior
to treatment. Prior to treatment, baseline imaging was performed by MRI
scan of brain and CT scan of the chest/abdomen/pelvis with i.v. contrast.
Peptides. gp100-derived peptides G154 (KTWGQYWQV), G209-2M
(IMDQVPFSV), and G280-9V (YLEPGPVTV) and CMV pp65–derived
peptide 495 (NLVPMVATV) were obtained lyophilized (>95% purity; American Peptide Company). Peptides were dissolved in 1% DMSO in sterile
water and tested for sterility, purity, endotoxin, and mycoplasma.
Cyclophosphamide treatment and DC preparation. Cyclophosphamide (300
mg/m2) was given 72 hours prior to D1 with the intention of eliminating
Tregs (61). Treg quantification was performed as described in Supplemental Figure 2. All mDC vaccine doses were prepared at the time of immunization from either freshly isolated (D1) or cryopreserved (D2–D6) PBMCs
(all derived from the same leukapheresis collection). A GMP-grade CD40Lexpressing K562 cell line (referred to as K463H), used for maturation of
DCs, was generated, selected, and maintained under serum-free (Stemline,
S1694 media) conditions (see Supplemental Figure 1). For each vaccine
dose, monocyte-derived iDCs were generated as described previously (62)
by culturing the PBMC adherent fraction in RPMI 1640 with 1% human
AB-serum (DC media) supplemented with 100 ng/ml GM-CSF (Berlex)
and 20 ng/ml IL-4 (CellGenix). 6 days after culture initiation, iDCs were
harvested, washed in PBS, and cultured for an additional 24 hours in DC
media (iDC control) or DC media with irradiated (100 Gy) K463H (5:1
DC/K463H ratio) and 100 U/ml IFN-γ (Actimmune; InterMune Inc.) to
generate mDCs. Comparison of the K463H line with other commercially available CD40L reagents in IL-12p70 induction is shown in Supplemental Figure 1, B and C. 2 hours prior to infusion, mDCs were pulsed
(50 μg/106 cells/ml) separately with 1 of 4 peptides: G154, G209-2M, G2809V, or CMV pp65. For D1 only, influenza virus vaccine (Sanofi Pasteur) was
added to provide a source of recall antigen for CD4+ T cells. For infusion,
mDCs were resuspended in 50 ml normal saline supplemented with 5%
human serum albumin and administered over 30 minutes by i.v. infusion
after premedication with 650 mg acetaminophen.
DC immunizations. mDC infusions were given i.v. every 3 weeks for 6
doses in the outpatient clinic. A restaging CT scan of the chest/abdomen/
pelvis with i.v. contrast was performed after D3 and D6 and then every
2 months thereafter until disease progression. If clinical or radiographic
disease progression was evident, the patient was removed from the study.
For D1, patients received 1.5 × 107 DCs per peptide (6 × 107 DCs total);
for D2–D6, patients received 5 × 106 DCs per peptide (2 × 107 DCs total).
The purpose of this trial was to determine the safety, tolerability, and clinical and immunological outcomes of immunization using peptide-pulsed
CD40L/IFN-γ mDCs. Patients underwent clinical evaluation prior to each
mDC infusion. Toxicities and adverse effects were graded according to the
National Cancer Institute Common Toxicity Scale (version 3.0). Clinical
response was assessed by measurement of assessable metastatic deposits by
CT scan, MRI scan, or direct measure of cutaneous deposits. The RECIST
(v1.0) group system was used (24).
Immunologic monitoring. Immunologic analysis to evaluate the kinetics
and magnitude of T cell response to gp100 peptides was performed using
PBMCs collected weekly (prior to vaccination and until week 21; Figure
1B). Fresh PBMCs obtained by Ficoll-Hypaque gradient centrifugation
were adjusted to 2 × 106 cells/ml in Stemline media (Sigma-Aldrich) containing 5% human AB-serum, and dispersed at 1 ml/well in 24-well plates.
Cultures were set up for the gp100 peptides and the CMV pp65 peptide
(positive peptide control; data not shown). Cultures were pulsed with 40
μg/ml peptide and 50 U/ml IL-2 fed starting at 48 hours and every other
day thereafter. On day 12 (peak of response; our unpublished observation),
cultures were harvested, counted, and stained for flow cytometry analysis.
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To assess the antigen-specific T cell frequency, cells were stained with HLAA*0201/peptide tetramers (Beckman Coulter) for 30 minutes at room temperature, followed by addition of FITC-conjugated CD4, CD14, CD19, and
CD56 and allophycocyanin-conjugated CD8 (Invitrogen) for 15 minutes at
4°C. Cells were washed and resuspended in FACS buffer, and 7AAD was
added 5 minutes before analysis. Control CMV pp65–specific CD8+ T cells
were detected in all CMV-seropositive patients before and after immunization (data not shown). A negative HLA-A*0201/HIV gag peptide tetramer
control was included. 25,000 events in the CD8+ gate were collected using
a hierarchical gating strategy that included FSC/SSC and excluded 7AAD+
(dead) cells and CD4+CD14+CD19+CD56+ cells. Data were acquired and
analyzed using Flow-Jo software.
Cytokine production. DC IL-12p70 and IL-12p40 production was measured by ELISA (eBioscience) according to the manufacturer’s instructions. Production of additional cytokines and chemokines by DCs was
determined using MILLIPLEX map Human Cytokine Panels I and II (EMD
Millipore). For production of cytokines by T cells, G280-9V–specific
T cells were expanded using mDCs and AT-SCT as described previously
(25). The frequency of antigen-specific T cells after secondary stimulation
was 2%–52%, as determined by HLA-A*0201/peptide tetramers (NIH tetramers Facility or Beckman Coulter). T cells were restimulated as described
previously (25), supernatants were collected at 24 hours, and production of
cytokines was determined using MILLIPLEX map Human Cytokine Panel
I (EMD Millipore).
qRT-PCR. qRT-PCR was performed as described previously (26). cDNAs
were prepared (2 μg total RNA), and cDNA samples were amplified in triplicate using a GeneAmp 5700 sequencer detector (Applied Biosystems).
Primers used were IL-12p35 (Hs00168405_m1) and ITGAX (integrin alpha
X, referred to herein as CD11c; Hs01015070_m1). Transcript levels were
calculated using the relative standard curve method, using CD11c transcript levels to normalize values.
51Cr release and T2 assays. 51Cr release assays to measure specific lysis
have been described previously (26, 62). Melanoma cell lines DM6 (HLAA2+gp100+) and A375 (HLA-A2+gp100–) were labeled with 25 μCi 51Cr for
1 hour, washed, and tested as targets in a standard 4-hour assay. Effectors
were generated using PBMCs collected after D3 and cultured for 12 days
in the presence of peptide (40 μg/ml) and IL-2 (50 U/ml every other day).
Vaccine-induced antigen-specific T cells were characterized using HLAA*0201/peptide dextramers (Immudex). To determine the avidity (effective
concentration at 50% maximal lysis) of vaccine-induced T cells for antigen,
T2 cells were pulsed with titrated G209-2M or G280-9V peptide concentrations for 1 hour in serum-free media followed by 51Cr (25 μCi) labeling
for 1 hour, washed twice, and tested using vaccine-induced gp100-specific
T cells in a standard 4-hour assay.
Statistics. Student’s t tests were 2-tailed (GraphPad Prism software, version
5.0). Data are presented as mean ± 1 SD, unless otherwise indicated. Cox
regression analysis followed by likelihood-ratio test was used to evaluate
whether (loge) IL-12p70 (sum) production added statistically significant
information to a model of TTP. Kaplan-Meier TTP model was used to test
whether cytokine ratios added statistically significant information to a
model of TTP. Wilcoxon matched-pairs analysis was used to compare IL12p70 production between patients and healthy donors (GraphPad Prism
software, version 5.0). All P values less than 0.05 were considered significant,
except the Cox proportional hazard model, which used a lower threshold
of significance (P < 0.048) to adjust for 1 interim analysis of this endpoint.
Study approval. This study (IRB no. 07-0652) was approved by the Siteman Cancer Center Protocol Review and Monitoring Committee and the
Washington University School of Medicine Human Research Protection
Office. All patients provided written informed consent for the clinical
study. The FDA approved procedures for DC manufacturing and admin-
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istration according to BB-IND 13590. All healthy volunteers and patients
that did not receive treatment on study provided written informed consent
prior to blood donation.
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